Shaanxi Panlong Pharmaceutical Group Co. Ltd. has disclosed proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) targeting moiety via linker acting as 3CLpro (SARS-CoV-2) degradation inducers reported to be useful for the treatment of SARS-CoV-2 infection.
Ice, juice, the exact measure of liquor, a few drops of Angostura... What goes into a good New Year’s Eve cocktail? According to researchers working on vaccines for the most elusive viruses, it will be time soon to toast next-generation vaccines. If 2020 was the year of the COVID-19 pandemic, and in 2021 the year of mRNA vaccinations, 2022 brought polyvalent designs of antigens, evaluated highly neutralizing antibodies, and fine-tuned mRNA technology against SARS-CoV-2, HIV and the flu.
Pardes Biosciences Inc. has patented 3C-like proteinase (3CLpro; Mpro; nsp5) inhibitors (particularly HCoV-229E virus and/or SARS-CoV-2 Mpro inhibitors). They are reported to be potentially useful for the treatment of SARS-CoV-2 infections (COVID-19).
Eleven vaccines have now been approved by the World Health Organization for preventing COVID-19, but all exhibit drastically reduced activities after 6 months. Unlike vaccines that express only the spike protein as the immunogen, live attenuated vaccines have the potential to confer a broader and more durable protection.
Emory University has identified deuterated and/or methylated N4-hydroxycytidine (NHC) analogues reported to be useful for the treatment of viral infections.
Ethris GmbH has entered into a collaboration with Diosynvax Ltd. to jointly develop a protective mRNA vaccine candidate against a broad range of betacoronaviruses utilizing the company's highly differentiated mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilization platforms.
RQ Biotechnology Ltd. (RQ Bio) has announced that the first of its discovered monoclonal antibodies to prevent COVID-19 in vulnerable patients, AZD-3152, has entered clinical trials.
RSS
